Amica Mutual Insurance Co. Sells 1,672 Shares of Eli Lilly and Company (NYSE:LLY)

Amica Mutual Insurance Co. reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 9.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 16,316 shares of the company’s stock after selling 1,672 shares during the quarter. Eli Lilly and Company accounts for about 1.0% of Amica Mutual Insurance Co.’s investment portfolio, making the stock its 24th largest holding. Amica Mutual Insurance Co.’s holdings in Eli Lilly and Company were worth $9,511,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently made changes to their positions in the business. JGP Wealth Management LLC boosted its position in Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after acquiring an additional 16 shares in the last quarter. Patton Albertson Miller Group LLC lifted its stake in shares of Eli Lilly and Company by 2.8% in the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after purchasing an additional 17 shares during the period. Valley Wealth Managers Inc. boosted its position in shares of Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after purchasing an additional 17 shares in the last quarter. Sandy Cove Advisors LLC grew its stake in Eli Lilly and Company by 0.8% in the fourth quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock worth $1,307,000 after purchasing an additional 17 shares during the period. Finally, Lathrop Investment Management Corp raised its holdings in Eli Lilly and Company by 1.2% in the third quarter. Lathrop Investment Management Corp now owns 1,476 shares of the company’s stock worth $793,000 after purchasing an additional 18 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY traded up $3.82 during midday trading on Monday, hitting $737.33. 2,726,536 shares of the company traded hands, compared to its average volume of 3,017,770. The company’s 50-day moving average is $760.89 and its 200 day moving average is $668.00. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $700.58 billion, a PE ratio of 127.13, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $392.26 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the firm earned $2.09 earnings per share. The firm’s revenue for the quarter was up 28.1% compared to the same quarter last year. On average, research analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on LLY shares. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Bank of America raised their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, Barclays raised their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.